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Summary
Objective: To analyze Epstein—Barr virus (EBV) load at different HIV infection stages and its
relation with brain lymphoma.
Design: A cross-sectional study was conducted on 172 HIV-infected individuals: 62 asymptomatic
HIV carriers (group A), 30 HIV progressors (group B), 73 AIDS patients (group C), seven AIDS
patients with brain lymphoma (group C-BL); and 26 blood donors (group BD) as healthy carriers.
EBV load was measured in peripheral blood mononuclear cells (PBMC) and plasma samples using a
semi-quantitative PCR method.
Results: PBMC-EBV levels in HIV-infected patients were higher than in the blood donors
(p < 0.05). No differences in PBMC-EBV loads were found in groups A, B, or C ( p > 0.05), while
the C-BL group had significantly lower levels (p < 0.05). Similar PBMC-EBV loads were seen in HIV-
infected patients with CD4+ T cell counts higher than 50/mm3 ( p > 0.05), while significantly
lower levels were found in cases with less than 50 cells/mm3 (p < 0.05). In all HIV-infected
patients, plasma-EBV load was lower than, or similar to, PBMC-EBV load, unlike 2/7 HIV-positive
brain lymphoma patients.
Conclusions: During HIV infection PBMC-EBV load rises in comparison to healthy carriers, but
decreases when immunosuppression progresses and CD4+ T cell count becomes <50/mm3.* Corresponding author. Tel.: +55 11 4301 7428/4302 5064; fax: +55 11 4302 5064/4303 2210.
E-mail address: oncovir1@anlis.gov.ar (M.D. Fellner).
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Circulating EBV is mainly cell-associated in the HIV-infected population. Neither PBMC-EBV nor
plasma-EBV loads would be useful to diagnose brain lymphoma in AIDS patients.
# 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Epstein—Barr virus (EBV) is a widely spread human gamma-
herpesvirus, whose prevalence exceeds 95% of the adult
human population.1 After the primary infection, as EBVestab-
lishes persistence in B lymphocytes, it can be detected both in
lymphoid tissue and peripheral blood.2,3 In immunosuppressed
patients, the virus—host imbalance favors EBV reactivation
which in turn induces lymphoproliferation.4 Therefore, it has
been proposed that these benign proliferations may become
malignant lymphomas if they are not well controlled by the
host immune system, although this is a rare event.5
EBV has been associated with a variety of malignancies
due to its detection in malignant cells.6—9 The EBV-associated
tumors described in the HIV-infected population include
non-Hodgkin lymphomas, Hodgkin lymphomas, Burkitt lym-
phomas, and smooth muscle malignancies. The strength of
association differs, being about 100% in cases of primary
brain lymphomas, which appear when patients are pro-
foundly immunosuppressed; in this sense, they are essen-
tially analogous to post-transplant lymphoproliferative
disorder (PTLD) lesions of the transplant group.4,10
In the transplant population a relationship was found
between circulating EBV load and PTLD.11,12 Moreover, higher
circulating EBV DNA levels precede PTLD diagnosis, which
allows for early therapeutic intervention in patients with
rising levels of EBV, thus preventing the establishment of this
life-threatening entity; also other reports noted decreased
EBV load with successful therapy.13—15
The EBV load has been much less studied in the HIV-
infected group than in transplant individuals. As in transplant
patients, frequent reactivation of EBV infection has been
observed in HIV-infected individuals, reflected by increased
EBV-specific antibody titers,16—18 and more recently, high
numbers of circulating copies of EBV.19,20 However, contro-
versy persists regarding the usefulness of measuring EBV
levels in AIDS patients in relation to lymphoma risk, diag-
nosis, and management.21—25
The semi-quantitative PCR (SQ-PCR) method used to mea-
sure EBV load was developed in our laboratory to monitor
transplant patients and in fact, its usefulness was demon-
strated for the detection of differences in circulating levels
of EBV DNA. Although different strategies such as competi-
tive methods or real time PCR have proven to yield the best
results, the SQ-PCR method is, for us, more affordable.26
The aim of our study was to analyze the EBV load in
different HIV infection stages and its relation with primary
brain lymphoma.
Materials and methods
Study population
One hundred and seventy-two HIV-infected patients from the
‘‘J.F. Mun˜iz’’ Infectious Diseases Hospital (Buenos Aires,Argentina) were included in this study. All of them were
receiving antiretroviral therapy, with the exception of
asymptomatic HIV-infected patients with CD4+ Tcells counts
above 350/mm3. Mean patient age was 26 years (range 16—61
years), male/female ratio was 2:3, and they were grouped
according to the 1993 CDC classification,27 as follows: 62
asymptomatic HIV-infected patients (group A), 30 HIV pro-
gressors (group B), 73 AIDS patients (group C), and seven AIDS
patients with a diagnosis of primary central nervous system
lymphoma (PCNSL) (group C-BL). They were all typed as non-
Hodgkin lymphoma according to the WHO classification.
Twenty-six blood donors (group BD), who were healthy
EBV carriers from the same hospital, were also included.
They were all negative for the usual blood bank tested
infections; mean age of this group was 34 years (range
19—50 years).
All the study population showed previous evidence of EBV
infection (presence of IgG antibodies against viral capsid
antigen (VCA) detected by indirect immune fluorescence
assay). All participants gave their informed consent for
inclusion in this study. A local ethics committee approved
all procedures.
Samples
EDTA anti-coagulated blood samples were collected and
peripheral blood mononuclear cells (PBMC) separated from
plasma after a Ficoll-Hypaque gradient centrifugation (Lym-
phoprep, GIBCO). Fresh brain biopsy tissue (BB) and in some
cases cerebrospinal fluid (CSF) were obtained from C-BL
patients. All samples were stored at 20 8C until used.
Paraffin embedded lymphoma tissue was examined with in
situ hybridization (ISH).
DNA extraction
DNA from PBMC, plasma, and BB was extracted with protei-
nase K lysis buffer and purified by a phenol—chloroform
procedure.28 DNA from CSF was extracted as previously
described.29
EBV quantification
Viral load was determined applying a semi-quantitative
method as we have previously described.26 This method
was developed to detect high EBV loads, i.e., levels above
those found in healthy carriers (latent state). Briefly, a nested
PCR was performed, which amplifies a fragment of 122 bp
from the BWRF1 gene. For PBMC, DNA equivalent to 105 cells
(366 ng) and its serial four-fold dilutions were amplified until
limiting dilution was reached. The amplified products were
run in a 2% agarose gel stained with ethidium bromide and the
end point was converted into viral copies/105 PBMC by multi-
plying the sensitivity of the assay (1—16 copies) by the reci-
procal of the limiting dilution (RLD). We subsequently applied
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Figure 1 Detection of PCR inhibitors. No inhibition was detected in DNA extracted from PBMC samples, while two DNA samples
extracted from plasma exhibited inhibitors. Both samples were re-extracted, and when re-tested one showed no inhibitors so it was
quantified, while the other was discarded since inhibitors could not be eliminated. (A) Detection of PCR inhibitors in DNA extracted
from PBMC samples. Lanes 1—5: DNAPBMC from HIV positive patients. Lane 6: negative control. Lane 7: positive control. Lane 8: 100 bp
ladder. (B) Detection of PCR inhibitors in DNA extracted from plasma samples. Lane 1: 100 bp ladder. Lanes 2—6: DNAplasma from HIV
positive patients. Notice the presence of inhibitors in the plasma specimen run in lane 2. Lane 7: negative control. Lane 8: positive
control.the method to plasma samples; the intra- and inter-assay
variation result was the same as for PBMC specimens, i.e., 
one four-fold dilution (data not shown). Thus, we considered
the same sensitivity and reproducibility as was described for
PBMC samples. For plasma specimens, DNA obtained from
30 mL (similar to the volume associated with 105 PBMC)14 and
its serial four-fold dilutions were amplified and quantified as
mentioned. The presence of PCR inhibitors was determined
when EBV load was <1 copy/105 PBMC or 30 mL of plasma as
follows: (A) Inhibitors in DNA extracted from PBMC samples
were determined by amplifying the humanb-globin gene using
primer set PCO4 and GH20 to amplify a 268 bp DNA fragment
as described by Bauer et al.30 (B) Inhibitors in DNA extracted
from plasma samples were tested by spiking around 125 ng of
DNA obtained from human fibroblasts onto DNA extracted
from 30 mL of plasma, and then the human b-globin gene
was amplified as described above (Figure 1).Figure 2 EBV detection and PBMC viral load in the study popula
converted into viral copies/105 PBMC by multiplying the sensitivity of
(RLD); e.g. if RLD = 4, after multiplying by 1 and by 16, the correspond
line represents the detection level with the SQ-PCR. Bars show the m
group.EBV qualitative detection
For EBV DNA qualitative determination, DNA extracted from
50 ul of CSF or about 300 ng of DNABB were amplified by the
same nested PCR applied for quantification, using different
cycling conditions in the first round: 3 min at 94 8C, and forty
1-min cycles at 94 8C, 30 s at 58 8C, 1 min at 72 8C; and 10 min
at 72 8C.
EBERs detection
To determine EBV association with PCNSL, a commercial in
situ hybridization (ISH) method that detects EBV-encoded
RNA (EBERs) transcripts was applied on paraffin-embedded
lymphoma tissue sections mounted onto silane-coated glass
slides. Peptide nucleic acid (PNA) fluorescein isothiocyanate
(FITC)-labeled probes: EBER-specific, positive and negativetion. The limiting dilution value obtained for each patient was
the assay (1—16 copies) by the reciprocal of the limiting dilution
ing viral load ranges between 4 and 64. ND, not detected; dotted
edian RLD value with the confidence interval range (%) for each
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Figure 3 EBV detection and load levels in HIV infected patients according to CD4+ T cell counts. The total number of patients
included in this analysis is lower than that described in Figure 2 since CD4+ T cell counts were not available in 10 patients. ND, not
detected; dotted line represents the detection level with the SQ-PCR. Bars show the median RLD value with the confidence interval
range (%) for each group.
Figure 4 Correlation between plasma-EBV and PBMC-EBV
loads. A linear regression analysis of the natural logarithm of
the reciprocal of the limiting dilution (RLD) values obtained from
paired PBMC and plasma samples of 62 patients is represented
(r = 0.173; p = 0.219).RNA controls (Dakocytomation, Glostrup, Denmark), fol-
lowed by its detection with a PNA ISH detection kit (Dako-
cytomation, Glostrup, Denmark), were used according to
manufacturers’ instructions.
Number of CD4+ and CD8+ lymphocytes
These were determined by standard flow cytometry techni-
ques.
Statistical analyses
Categorical data were compared using Fisher’s exact test or
the Chi-square test, while the non-parametric Mann—Whit-
ney U test for unpaired data was used to analyze ordinal
values. For the purpose of the analysis, not-detected (ND)
RLD values were considered 0. The PEPI Program Finder
version 4.0 was used for the analyses. Linear regression
analysis was performed after RLD was converted into a
natural logarithm (Ln) with the Analyse-it software for Excel
1997—2000.
Results
EBV load and clinical HIV state
HIV-infected individuals were found to exhibit a signifi-
cantly higher detection rate and increased levels of circu-
lating EBV DNA compared to blood donors ( p < 0.05).
Similar results were obtained when comparing each HIV
clinical set without lymphoma to the BD group (Figure 2).
Also, no statistically significant differences ( p > 0.05) in
EBV detection and EBV load were found between groups A,
B, and C. The C-BL group was found to have a significantly
( p < 0.05) lower circulating EBV rate and levels compared
to groups A and B.EBV load and CD4+ T cells
EBV detection was similar in all groups with CD4+ Tcell counts
higher than 50/mm3 ( p > 0.05), and significantly higher than
in patients with less than 50 CD4+ T cells/mm3 ( p < 0.05).
When analyzing EBV levels, we found no statistically signifi-
cant differences between groups with more than 50 CD4+ T
cells/mm3. On the other hand, circulating EBV levels in
patients with less than 50 CD4+ T cells/mm3 were signifi-
cantly ( p < 0.05) lower than in those with CD4+ Tcells counts
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Table 1 Description of HIV-infected patients with primary central nervous system lymphoma
Patient Histopathologic
diagnosis
PCR EBER ISH PBMC-EBV load
(copies/105 PBMC)
Plasma EBV load
(copies/30 mL)
1 DLBCL + (BB) + <1 64—1024
2 DLBCL + (BB) + <1 <1
3 DLBCL + (BB) + <1 16—256
4 DLBCL + (BB) + 1—16 <1
5 DLBCL + (BB) + <1 <1
6 DLBCL + (BB) + <1 <1
7 DLBCL + (BB) NS <1 <1
+ (CSF)
DLBCL, diffuse large B cell lymphoma; BB, brain biopsy; NS, no sample available.between 50 and 500/mm3. Figure 3 illustrates the results of
EBV quantification as regards the number of CD4+ T lympho-
cytes.
EBV load and CD8+ T cells
No correlation was found between EBV circulating levels and
the number of CD8+ T cells in the HIV-infected population
studied (data not shown).
Relation between PBMC- and plasma-EBV load
Plasma-EBV load was measured in about 20 patients of each
HIV clinical set: A, B, and C (n = 55), and in all seven C-BL
cases. The criterion for plasma selection was that all PBMC-
EBV load ranks were represented. Therefore, when analyzing
EBV DNA in different peripheral blood compartments of all
HIV groups, we observed no correlation between PBMC and
plasma levels (Figure 4).
Also, EBV load was lower in plasma samples than in PBMC
for most HIV positive cases without lymphoma; only two
patients (from groups A and C) had similar circulating EBV
DNA copies in both samples. Two of the seven HIV-infected
patients with PCNSL had higher EBV levels in plasma than in
PBMC (patients 1 and 3, Table 1).
Discussion
In this project, we noted that in HIV-infected patients EBV in
peripheral blood is higher than in healthy individuals. Thus,
higher EBV DNA detection rates were found in PBMC of HIV-
infected patients compared to healthy individuals, in agree-
ment with the report by Ling et al.20 Contrary to this finding,
Dehee et al. described a similar EBV positivity rate in HIV-
infected patients and asymptomatic HIV negative volun-
teers.19 In the latter case, the percentage of EBV DNA
detection in HIV negative individuals was strikingly high
compared to other reports.20,21,29,31 These differences could
be due to the control groups, the methodological strategies,
or the sensitivity of the techniques. Also, increased PBMC-
EBV load was found in all the clinical HIV infection categories
(groups A, B, and C), indicating that the imbalance between
EBV infection and the host immunologic control starts early in
the course of HIV clinical infection, and continues as the
infection progresses. In a prospective study, Piriou et al.proved that PBMC-EBV load increases rapidly following HIV
seroconversion, and remains high even five years later, both
in asymptomatic carriers and AIDS progressors.24
Since CD4+ T cell depletion is the immunologic hallmark
of HIV-related disease progress,32,33 we also analyzed the
relation of circulating EBV levels and the progress of
immunological deterioration, according to CD4+ T cell
counts by the CDC classification. In agreement with reports
by Dehee et al.,19 and Ling et al.,20 when the number of
CD4+ T cells is greater than 50/mm3, higher levels of
circulating PBMC-EBV are seen in HIV-infected patients,
compared to healthy carriers. This situation may reflect
the loss of EBV infection control due to progressive immu-
nosuppression, similar to the situation widely described for
transplant patients subjected to severe immunosuppres-
sion.14,34—36 However, in HIV-infected patients with CD4+ T
cell counts under 50/mm3 we observed lower levels of
circulating PBMC-EBV, which counters the findings of Dehee
et al. who found increased PBMC-EBV DNA levels even in
this group (<50 LT CD4+/mm3).19 Our observations could be
explained if we consider that copies of peripheral EBV have
been detected only in memory B lymphocytes,37,38 cells
generated after a germinal center reaction.39,40 Thus, the
decline in the PBMC-EBV load could be due to the decrease
in circulating memory B lymphocytes observed during HIV
infection.41,42 This reduction may be due to hyperactiva-
tion-induced memory B cell exhaustion, increased apopto-
sis, on top of an abnormal naı¨ve B cell activation/
differentiation process.43 Therefore, we conclude that it
would be interesting to analyze EBV level variation relative
to the quantity of B lymphocytes at different stages of HIV
infection.
Like Dehee et al.,19 we found no correlation between total
CD8+ Tcell count and PBMC-EBV load. It should be pointed out
that van Baarle et al., studying HIV-infected patients, ana-
lyzed the EBV-specific CD8+ T cell population (which repre-
sents a small proportion of total CD8+ T lymphocytes), and
observed a normal number, although with decreased func-
tional capacity, compared to HIV negative individuals.44
Also, our study shows that in HIV-infected patients, the
EBV found in peripheral blood is carried mainly in PBMC (cell-
associated virus), in agreement with Stevens et al.,23
although our study analyzed a substantially larger number
of patients. Moreover, we observed no correlation between
PBMC-EBV and plasma-EBV loads, as reported by van Baarle
et al.22 and Righetti et al.45 Further, the plasma-EBV levels of
EBV in HIV-infected patients and primary brain lymphoma 177HIV-infected patients without lymphoma were lower or simi-
lar to those found in PBMC which could indicate that the EBV-
plasma load results from the lysis of latently-infected circu-
lating B cells (necrosis or apoptosis), or that peripheral lytic
infection (either the presence of circulating EBV-virions and/
or lysis of circulating EBV-activated B cells) is not the main
cause of increased circulating EBV, or both. It would be
interesting for future studies to establish whether plasma-
EBV load corresponds to encapsulated virions or nude viral
DNA.
Different authors have described variable circulating EBV
DNA levels when lymphoma is diagnosed in HIV-infected
patients.21,31 Also, prospective studies by van Baarle et al.
have shown that HIV-infected patients with non-Hodgkin
lymphomas have EBV levels that fluctuate over time, being
at the time of lymphoma diagnosis lower, similar to, or higher
than those previously detected.22,44 Recently, Fan et al.
described significantly higher plasma-EBV levels in HIV-
infected patients with EBV-associated lymphomas compared
to HIV-infected patients with non-EBV-associated lympho-
mas, or without lymphomas. However, plasma-EBV load var-
ied in the samples collected before, during, and after
lymphoma diagnosis, although EBV DNA was detectable at
least in one sample. It was noted that in primary brain
lymphoma cases, the EBV load was mainly not detectable
at the time of diagnosis.25
In this study, the PBMC-EBV load in AIDS patients with
PCNSL (group C-BL) was lower than that found in the initial
stages of HIV infection (groups A and B), albeit similar to the
levels found in AIDS patients without lymphoma (group C).
Further, PBMC-EBV levels were undetectable or low in all
patients with PCNSL diagnosis, seeming to indicate that EBV
load determination would not be a useful indicator of lym-
phoma, even though only few cases were analyzed. Since
PCNSL is a pathology found in HIV-infected patients with
advanced immunological deterioration, our findings could
be accounted for, as previously mentioned, by the decrease
in memory B lymphocytes, described in the course of HIV
infection. Moreover, although most of the lymphoma
patients showed undetectable plasma-EBV load, it was
higher, even more than PBMC-EBV levels, in two cases,
suggesting increased lysis of latently-infected circulating
B cells, and/or peripheral lytic infection, at least in some of
these patients. In this sense, it would also be interesting to
determine whether plasma-EBV load in HIV-infected
patients with lymphoma corresponds to virions or to nude
DNA.
In conclusion, EBV found in peripheral blood of HIV-
infected patients is mainly cell-associated. Also, during
the course of HIV infection, when the CD4+ T cell count is
above 50/mm3, the PBMC-EBV levels are increased, which
would reflect the loss of EBV infection control due to pro-
gressive immunosuppression. When immunological dete-
rioration progresses and the CD4+ T cell count is below 50/
mm3, the PBMC-EBV load decreases; perhaps because of
altered B lymphocytes (memory and naı¨ve) distribution,
and inappropriate activation/differentiation that have been
described in the course of HIV infection. Also, the determi-
nation of the PBMC-EBV load in AIDS patients with PCNSL
would not be a useful indicator of lymphoma, while the
meaning of EBV DNA in these patients’ plasma remains to
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